Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Sam Finn, a senior research associate at Zymo Research working with the Oncology Diagnostic Team, helped to host this interactive game booth at the “BioFestival” on Tuesday.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

This complex microbial dance seems to have a really important role in our health. Oral diseases and even oral cancers have ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...